Novartis AG NVS announced mixed results from the phase III IRIDIUM study on investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF). QVM149 demonstrated statistically significant improvement in lung function as compared to QMF149 (indacaterol acetate and mometasone furoate or IND/MF), thereby meeting the primary endpoint in asthma patients, whose disease was uncontrolled on treatment with a long-acting beta agonist/inhaled corticosteroid (LABA/ICS). However, the key secondary endpoint — improvement in the Asthma Control Questionnaire (ACQ-7) score for IND/GLY/MF versus IND/MF — was not met […]